Four years after Omeros came up short in its bid to gain an FDA approval for stem cell transplant drug narsoplimab, the ...

After ushering in a new era of obesity treatment with its GLP-1 medicine Wegovy earlier in the decade, Novo Nordisk is making ...

Johnson & Johnson’s $14.6 billion buyout of Intra-Cellular in the first mo | Of the top 10 biopharma M&A deals of 2025, six ...

A patient in an open label extension study of Pfizer’s hemophilia treatment Hympavzi has died, the company and several ...

Already boasting an outsized presence in its home country of South Korea, CDMO juggernaut Samsung Biologics is making ...

Nine large pharma companies have reached agreements with the Trump administration to lower certain drug prices in the U.S. | ...

In a merger of rare disease specialists, BioMarin has agreed to acquire Amicus Therapeutics for $4.8 billion. The California ...

Pharma's end-of-year dealmaking flurry is not showing signs of slowing, as, now, two Japanese drugmakers have joined the ...

With a second late-stage trial win for its investigational HIV combo in the books, Gilead Sciences is moving full steam ahead ...

Seven years after the FDA's accelerated approval of bleeding reversal agent Andexxa, which was then under the ownership of ...

In the last Fierce Pharma Asia weekly news roundup of 2025, Daiichi Sankyo scored a key FDA approval for ...

Medtronic initially secured FDA clearance for the MiniMed 780G pump for people with Type 1 diabetes in early 2023. This past ...